SIGLEC15 and cancer: (27) first supported that SIGLEC15 could be an immune suppressor and potential target for normalization cancer immunotherapy by using a genome-scale T-cell activity array in 2019, and they also revealed upregulation of SIGLEC15 on various cancer types.